Solasia Pharma K.K. announced that episil oral liquid has been launched in South Korea by its commercialization and promotion partner, Synex Consulting Ltd. the company obtained an exclusive license to develop and commercialize episil in Japan, China, and South Korea from Sweden-based Camurus AB. episil was launched in Japan in 2018 with the approval of the Ministry of Health, Labour and Welfare, and in China in 2019 with the approval of the National Medical Products Administration. In South Korea, episil was approved from the National Institute of Medical Device Safety Information in 2019 and now launched by company's sales partner, Synex. The impact of this event has been already included in the current fiscal year's financial forecast, thus no change in financial forecast will be announced as of now. However, the contribution to the company's financials is expected to affect over medium to long term.